References for Humility and Hope, Alvarnas

https://doi.org/10.37765/ajmc.2020.435631. Lawrence TE (story). Bolt R, Wilson M (screenplay). Lawrence of Arabia [film]. United Kingdom: Horizon Pictures; 1962. imdb.com/title/tt0056172/?ref_=fn_al_tt_1

2. CDC. Pneumocystis pneumonia — Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30(21):250-252.

3. CDC. First report of AIDS. MMWR Morb Mortal Wkly Rep. 2001;50(21):429.

4. du Bois RM, Branthwaite MA, Mikhail JR, Batten JC. Primary Pneumocystis carinii and cytomegalovirus infections. Lancet. 1981;318(8259):1339. doi:10.1016/S0140-6736(81)91353-2

5. Pickrell J. Timeline: HIV and AIDS. New Scientist. September 4, 2006. Accessed May 19, 2020. newscientist.com/article/dn9949-timeline-hivand-aids/

6. A timeline of HIV and AIDS. HIV.gov. Accessed May 19, 2020. hiv.gov/federal-response/ending-the-hiv-epidemic/overview/endingepidemic-timeline

7. CDC. Current trends update on Acquired Immune Deficiency Syndrome (AIDS)—United States. MMWR Morb Mortal Wkly Rep. 1982;31(37):507-508, 513-514. https://www.cdc.gov/mmwr/preview/mmwrhtml/00001163.htm

8. Altman LK. New U.S. report names virus that may cause AIDS. The New York Times. April 24, 1984. Accessed May 19, 2020. nytimes.com/1984/04/24/science/new-us-report-names-virus-that-may-causeaids.html

9. History of HIV and AIDS overview. Avert. Updated October 10, 2019. Accessed May 23, 2020. avert.org/professionals/history-hiv-aids/overview

10. Sharp P, Hahn BH. The evolution of HIV-1 and the origin of AIDS. Philos Trans R Soc Lond B Biol Sci. 2010;365(1552):2487-2494. doi:10.1098/rstb.2010.0031

11. Fehervari Z. Origin story. Nature Research. November 28, 2018. Accessed May 23, 2020. https://nature.com/articles/d42859-018-00008-6

12. CNN. Researchers trace first HIV case to 1959 in the Belgian Congo. CNN Interactive. February 3, 1998. Accessed May 23, 2020. cnn.com/HEALTH/9802/03/earliest.aids/

13. Sharp P, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011;1(1):a006841. doi:10.1101/cshperspect.a006841

14. Hendrix S. A mystery illness killed a boy in 1969. years later, doctors believed they’d learned what it was: AIDS. The Washington Post. May 15, 2019. Accessed May 23, 2020. washingtonpost.com/history/2019/05/15/mystery-illness-killed-boy-years-later-doctorslearned-what-it-was-aids/

15. Global Health Observatory (GHO) data: HIV/AIDS. World Health Organization. Accessed May 23, 2020. who.int/gho/hiv/en/

16. CDC. Update: trends in AIDS incidence — United States, 1996. MMWR Morb Mortal Wkly Rep. 1997;46(37);861-867.

17. Mellors JW, Rinaldo CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272(5265):1167-1170. doi:10.1126/science.272.5265.1167

18. Feinberg MB. Changing the natural history of HIV disease. Lancet. 1996;348(9022):239-246. doi:10.1016/s0140-6736(96)06231-9

19. Vella S. XI International AIDS Conference: new antiretroviral therapy guidelines. NEJM Journal Watch. October 1, 1996. Accessed May 19,

2020. jwatch.org/ac199610010000002/1996/10/01/xi-international-aids-conference-new

20. Scaccia A, Madell R. Facts about HIV: life expectancy and long-term outlook. Healthline. Reviewed April 27, 2018. Accessed May 23, 2020. healthline.com/health/hiv-aids/life-expectancy

21. HIV mortality slide series through 2015. CDC Stacks Public Health Publications. August 13, 2018. Accessed May 23, 2020. https://stacks.cdc.gov/view/cdc/58351

22. AIDS drugs have saved 3 million years of life in the United States. News release. National Institute of Allergy and Infectious Diseases; June 2,

2006. Accessed May 23, 2020. nih.gov/news-events/news-releases/aidsdrugs-have-saved-3-million-years-life-united-states

23. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med.

2009;360(7):692-698. doi:10.1056/NEJMoa0802905

24. Mandavilli A. The ‘London Patient,’ cured of HIV, reveals his identity. The New York Times. Published March 9, 2020. Accessed May 23, 2020. nytimes.com/2020/03/09/health/hiv-aids-london-patient-castillejo.html

25. Bavinton BR, Rodger AJ. Undetectable viral load and HIV transmission dynamics on an individual and population level: where next in the

global HIV response? Curr Opin Infect Dis. 2020;33(1):20-27. doi:10.1097/QCO.0000000000000613

26. Reitsema M, van Hoek AJ, van der Loeff MS, et al. Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness. AIDS. 2020;34(4):621-630. doi:10.1097/QAD.0000000000002469

27. Selik RM, Mokotoff ED, Branson B, et al. Revised surveillance case definition for HIV infection — United States, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(RR03):1-10. cdc.gov/mmwr/preview/mmwrhtml/rr6303a1.htm

28. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60(12):1365-1372. doi:10.1136/jcp.2007.051953

29. Achenbach CJ, Buchanan AL, Cole SR, et al; Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS). HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy. Clin Infect Dis. 2014;58(11):1599-1606. doi:10.1093/cid/ciu076

30. Levine AM. Acquired immunodeficiency syndrome—related lymphoma. Blood. 1992;80(1):8-20.

31. Vishnu P, Aboulafia DM. AIDS-related non-Hodgkin’s lymphoma in the era of highly active antiretroviral therapy. Adv Hematol. 2012;2012:485943. doi:10.1155/2012/485943

32. Swiss HIV Cohort Study; Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort Study. Int J Epidemiol. 2010;39(5):1179-1189. doi:10.1093/ije/dyp321

33. Clifford GM, Polesel J, Rickenbach M, et al; Swiss HIV Cohort Study. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425-432. doi:10.1093/jnci/dji072

34. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB, et al. AIDS-related lymphoma. histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol. 1991;138(1):149-163.

35. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336(23):1641-1648. doi:10.1056/NEJM199706053362304

36. Boué F, Gabarre J, Gisselbrecht C, et al. Phase II trials of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24(25):4123-4128. doi:10.1200/JCO.2005.05.4684

37. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-1543. doi:10.1182/blood-2005-04-1437

38. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome—related lymphoma with dose-adjusted EPOCH: impact of antiretroviral suspension and tumor biology. Blood. 2003;101(12):4653-4659. doi:10.1182/blood-2002-11-3589

39. Sparano JA, Lee JY, Kaplan LD, et al; AIDS Malignancy Consortium. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115(15):3008-2016. doi:10.1182/blood-2009-08-231613

40. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SCEPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115(15):3017-3024. doi:10.1182/blood-2009-11-253039

41. Noy A, Kaplan L, Lee JY. A modified dose intensive R- CODOX-M/IVAC for HIV-associated Burkitt lymphoma and atypical Burkitt lymphoma (BL) demonstrates high cure rates and low toxicity: prospective multicenter trial of the AIDS Malignancy Consortium (AMC 048). Blood. 2013;122(21):639. doi:10.1182/blood.V122.21.639.639

42. Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART era. Adv Hematol. 2012;2012:735392. doi:10.1155/2012/735392

43. Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt’s lymphoma. AIDS. 2010;24(6):851-856. doi:10.1097/QAD.0b013e3283301578

44. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome—related Burkitt lymphoma/leukemia. Cancer. 2002;94(5):1492-1499.

doi:10.1002/cncr.10365

45. Kojima Y, Hagiwara S, Uehira T, et al. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan. Jpn J Clin Oncol. 2014;44(4):318-323. doi:10.1093/jjco/hyu012

46. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369(20):1915-1925. doi:10.1056/NEJMoa1308392

47. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associate non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122(19):3251-3262. doi:10.1182/blood-2013-04-498964

48. Alvarnas JC, Le Rademacher J, Wang Y, et al. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016;128(8):1050-1058. doi:10.1182/blood-2015-08-664706

49. Ambinder RF, Wu J, Logan B, et al. Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 Trial. Biol Blood Marrow Transplant. 2019;25(11):2160-2166. doi:10.1016/j.bbmt.2019.06.033

50. Alvarnas JC, Zaia JA, Forman SJ. How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation. Blood. 2017;130(18):1976-1984. doi:10.1182/blood-2017-04-551606

51. Division of HIV/AIDS Prevention. Statistic overview. CDC. Updated May 18, 2020. Accessed May 23, 2020. cdc.gov/hiv/statistics/overview/index.html

52. Overbaugh J, Morris L. The antibody response against HIV-1. Cold Spring Harb Perspect Med. 2012;2(1):a007039. doi:10.1101/cshperspect.a007039

53. Deng K, Pertea M, Rongvaux A, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature.

2015;517(7534):381-385. doi:10.1038/nature14053

54. Harris JE. Why we don’t have an HIV vaccine, and how we can develop one. Health Aff (Millwood). 2009;28(6):1642-1654. doi:10.1377/hlthaff.28.6.1642

55. HHS. HIV/AIDS glossary: life cycle. AIDSinfo. Accessed May 23, 2020. aidsinfo.nih.gov/understanding-hiv-aids/glossary/1596/life-cycle

56. Milone MC, O’Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529-1541. doi:10.1038/s41375-018-0106-0

57. Vink CA, Counsell JR, Perocheau DP, et al. Eliminating HIV-1 packaging sequences from lentiviral vector proviruses enhances safety and expedites gene transfer for gene therapy. Mol Ther. 2017;25(8):1790-1804. doi:10.1016/j.ymthe.2017.04.028

58. Poorebrahim M, Sadeghi S, Fakhr E, et al. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Crit Rev Clin Lab Sci. 2019;56(6):393-419. doi:10.1080/10408363.2019.1633512

59. Kootstra NA, Matsumura R, Verma IM. 248. gene therapy for hemophilia A using lentiviral vectors. Mol Ther. 2002;5(5):S82. doi:10.1016/S1525-

0016(16)43078-9

60. Learn more. National AIDS Memorial. aidsmemorial.org/theaidsquilt-learnmore/ Accessed May 23, 2020.

Download PDF: References for Humility and Hope, Alvarnas